Target Name: ELAVL1
NCBI ID: G1994
Review Report on ELAVL1 Target / Biomarker Content of Review Report on ELAVL1 Target / Biomarker
ELAVL1
Other Name(s): Hu-antigen R | ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) | ELAV1 | ELAV1_HUMAN | embryonic lethal, abnormal vision, drosophila, homolog-like 1 | Hu antigen R | MelG | HuR | Hua | HUR | ELAV like RNA binding protein 1 | hu-antigen R | ELAV-like protein 1

ELAVL1: A Potential Drug Target and Biomarker

ELAVL1, short for endoplasmic reticulum-associated degradation-related protein 1, is a protein that is expressed in various tissues and cells in the human body. It is a key regulator of protein degradation and has been implicated in a number of cellular processes, including cell signaling, inflammation, and neurodegeneration. As a result, ELAVL1 has emerged as a promising drug target and biomarker for a variety of diseases.

The discovery and characterization of ELAVL1

ELAVL1 was first identified as a protein that was expressed in the endoplasmic reticulum (ER) and was involved in the regulation of protein degradation. The ER is a protein-producing organelle that is responsible for the quality control and degradation of proteins that have been synthesized in the cytoplasm. The ER is also involved in the delivery of proteins to the plasma membrane for export to the extracellular environment.

ELAVL1 was shown to play a key role in regulating the degradation of several proteins, including the protein involved in the neurotransmittertransporter system, N-methyl-D-aspartate (NMDA) receptor, and the protein involved in the production of collagen. These studies suggested that ELAVL1 may be a useful drug target for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The potential clinical applications of ELAVL1 as a drug target

The potential clinical applications of ELAVL1 as a drug target are vast and varied. One of the main targets for ELAVL1 is the neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodegeneration.

ELAVL1 has been shown to be involved in the production of these neurodegenerative diseases by regulating the degradation of proteins that are involved in the development and maintenance of these conditions. For example, studies have shown that ELAVL1 can promote the production of tau tangles, a hallmark of Alzheimer's disease, and that it can also increase the levels of neurofibrillary tangles in the brain.

In addition to its role in the production of neurodegenerative diseases, ELAVL1 has also been shown to be involved in the regulation of normal brain function and the development of various psychiatric conditions, including depression and anxiety. This suggests that ELAVL1 may be a useful drug target for a variety of psychiatric conditions as well.

The potential biomarker applications of ELAVL1

ELAVL1 has also been shown to be a potential biomarker for a variety of diseases, including neurodegenerative diseases, cancer, and cardiovascular disease. This is because ELAVL1 is expressed in a variety of tissues and cells in the body and is involved in the regulation of protein degradation, which is a fundamental process that is involved in the development and progression of many diseases.

For example, studies have shown that ELAVL1 is expressed in the brains of individuals with Alzheimer's disease and that it is involved in the production of neurofibrillary tangles and tau tangles. This suggests that ELAVL1 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

In addition, ELAVL1 has also been shown to be involved in the regulation of protein degradation in cancer cells. This suggests that it may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a drug target and biomarker, ELAVL1 is also of interest to researchers as a potential therapeutic agent. Studies have shown that ELAVL1 can be inhibited using small molecules and that this can protect brain cells from neurodegeneration in animal models of

Protein Name: ELAV Like RNA Binding Protein 1

Functions: RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability (PubMed:14517288, PubMed:18285462, PubMed:31358969). Involved in embryonic stem cell (ESC) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESC differentiation (By similarity). Has also been shown to be capable of binding to m6A-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs (PubMed:32245947). Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:8626503, PubMed:17632515, PubMed:18285462, PubMed:23519412, PubMed:14731398). Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'-UUUU[AG]UUU-3' motif in vitro (PubMed:8626503). With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA (By similarity). Increases the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR (PubMed:29180010)

The "ELAVL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAVL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1